Insulet Co. (NASDAQ:PODD) Shares Bought by Creative Planning

Creative Planning increased its position in Insulet Co. (NASDAQ:PODD) by 35.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,430 shares of the medical instruments supplier’s stock after acquiring an additional 1,928 shares during the period. Creative Planning’s holdings in Insulet were worth $1,499,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock valued at $1,405,328,000 after buying an additional 169,506 shares in the last quarter. Baillie Gifford & Co. increased its holdings in Insulet by 30.8% during the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock valued at $380,607,000 after acquiring an additional 443,783 shares in the last quarter. William Blair Investment Management LLC increased its holdings in Insulet by 3.7% during the 1st quarter. William Blair Investment Management LLC now owns 952,268 shares of the medical instruments supplier’s stock valued at $163,219,000 after acquiring an additional 33,579 shares in the last quarter. American Century Companies Inc. raised its position in Insulet by 18.7% during the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock worth $178,728,000 after acquiring an additional 139,246 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Insulet by 56.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier’s stock valued at $190,623,000 after purchasing an additional 316,649 shares in the last quarter.

Insulet Stock Performance

NASDAQ:PODD opened at $229.33 on Wednesday. The company has a market cap of $16.06 billion, a P/E ratio of 69.49, a P/E/G ratio of 4.35 and a beta of 1.21. The firm’s 50 day moving average is $212.04 and its two-hundred day moving average is $193.64. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $243.98. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The firm had revenue of $488.50 million during the quarter, compared to analysts’ expectations of $488.00 million. During the same period last year, the business posted $0.38 earnings per share. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. Analysts expect that Insulet Co. will post 3.04 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PODD. BTIG Research cut their price objective on Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Barclays upped their price objective on Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. UBS Group lifted their price objective on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Citigroup boosted their target price on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Finally, Piper Sandler raised their price target on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus price target of $234.60.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.